RD Saúde, Brazil’s leading pharmacy chain, posted impressive financial results for the third quarter of 2024. The company’s performance exceeded market expectations, showcasing its resilience in a competitive landscape.
This report delves into the key figures and their implications for the company’s future. The adjusted net profit reached R$ 336.8 million ($59.1 million), marking a substantial 25.5% increase from the previous year.
This figure surpassed Bloomberg’s consensus estimate of R$ 292 million, demonstrating the company’s ability to outperform market predictions.
RD Saúde‘s adjusted EBITDA climbed to R$ 810.8 million ($142.2 million), representing a 23.2% year-over-year growth. The EBITDA margin improved to 7.5%, up 0.4 percentage points from the same period last year.
This margin expansion indicates enhanced operational efficiency. The company’s consolidated adjusted net sales and services revenue reached R$ 9.989 billion ($1.75 billion), growing by 15.29% compared to Q3 2023.
Gross revenue saw a 15.9% increase, totaling R$ 10.7 billion ($1.88 billion). These figures reflect strong consumer demand across various product categories.
Strong Expansion and Financial Performance
RD Saúde’s store network expanded to 3,139 pharmacies by the end of Q3 2024. The company opened 72 new stores and closed 9 during the quarter.
Over the past 12 months, the net addition of 291 stores underscores the company’s aggressive expansion strategy. Sales performance varied across product categories.
Generic medications led the growth with a 17% increase, followed closely by branded medications at 15.9%. OTC products grew by 15.3%, while perfumery saw a more modest 9.9% growth due to a strong comparison base from the previous year.
The company’s financial position remained robust, with positive free cash flow of R$ 700.6 million ($122.9 million). This represents a significant improvement from R$ 336.2 million in Q3 2023.
In addition, the adjusted net debt stood at R$ 2.871 billion ($503.7 million) at the end of September. RD Saúde’s Board of Directors approved a new share repurchase program.
The company plans to acquire up to 3,230,000 common shares over 18 months. This initiative aims to support long-term incentive programs with restricted shares, aligning employee interests with shareholder value.
The company‘s strong performance in Q3 2024 reaffirms its leading position in Brazil’s pharmaceutical retail market. RD Saúde’s continued expansion and robust financial results demonstrate its ability to navigate market challenges effectively.
The share repurchase program further underscores the company’s commitment to long-term growth and stakeholder value creation.
More: Brazil news in English, every day from The Rio Times.
Live Company IntelligenceRaia Drogasil S.A — the full investor dossier
This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.
Brazil runoff, Sunday, October 25: When is the Brazil runoff election. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.